Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
C12N-005/00
C12N-015/00
C12P-021/08
C07K-016/22
G01N-033/74
G01N-033/574
A61K-039/00
출원번호
US-0832803
(2015-08-21)
등록번호
US-9676846
(2017-06-13)
발명자
/ 주소
Dimitrov, Dimiter S.
Zhu, Zhongyu
Zhao, Qi
출원인 / 주소
The United States of America as represented by the Secretary, Department of Health and Human Services
대리인 / 주소
Klarquist Sparkman, LLP
인용정보
피인용 횟수 :
0인용 특허 :
65
초록▼
Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. N
Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.
대표청구항▼
1. An isolated nucleic acid molecule encoding a single chain Fv protein (scFv), wherein the scFv comprises a heavy chain variable region and a light chain variable region,wherein the heavy chain variable region comprises the amino acid sequence set forth as amino acids 26-33 of SEQ ID NO: 7, amino a
1. An isolated nucleic acid molecule encoding a single chain Fv protein (scFv), wherein the scFv comprises a heavy chain variable region and a light chain variable region,wherein the heavy chain variable region comprises the amino acid sequence set forth as amino acids 26-33 of SEQ ID NO: 7, amino acids 51-58 of SEQ ID NO: 7, and amino acids 97-109 of SEQ ID NO: 7, wherein residue 56 is G and residue 109 is N; andwherein the light chain variable region comprises the amino acid sequence set forth as amino acids 27-32 of SEQ ID NO: 8, amino acids 50-52 of SEQ ID NO: 8 and amino acids 89-97 of SEQ ID NO: 8, and wherein the scFv specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 200 pM or less and specifically binds IGF-I with an equilibrium dissociation constant (Kd) of 200 pM or less. 2. The isolated nucleic acid molecule of claim 1, operably linked to a promoter. 3. An expression vector comprising the isolated nucleic acid molecule of claim 1. 4. The expression vector of claim 3, wherein the heavy chain variable region is encoded by the nucleic acid sequence set forth as SEQ ID NO: 11 and wherein the light chain variable region is encoded by the nucleic acid sequence set forth as SEQ ID NO: 12. 5. An isolated host cell transformed with the nucleic acid molecule of claim 2. 6. A method of producing a single chain Fv protein (scFv) comprising: a) transforming a host cell in vitro with the vector of claim 3, wherein the scFv is expressed by the host cell; andb) purifying the scFv from the host cell, thereby producing the scFv. 7. The isolated nucleic acid molecule of claim 1, wherein the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 7, wherein residue 7 is L; residue 20 is V; residue 23 is K; residue 37 is V; residue 56 is G; residue 61 is A; residue 62 is Q; residue 74 is K; residue 76 is T; residue 77 is S; residue 79 is A; residue 85 is S; residue 87 is G; residue 109 is N; residue 111 is G; and residue 115 is L. 8. The isolated nucleic acid molecule of claim 1, further encoding a polypeptide label. 9. The isolated nucleic acid molecule of claim 8, wherein the polypeptide label is a fluorescent protein or an enzyme. 10. A composition comprising the isolated nucleic acid molecule of claim 1, and a pharmaceutically acceptable carrier. 11. The isolated nucleic acid molecule of claim 1 wherein the heavy chain variable region is encoded by the nucleic acid sequence set forth as SEQ ID NO: 19. 12. The isolated nucleic acid molecule of claim 1, wherein the light chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 8. 13. The isolated nucleic acid molecule of claim 1, wherein the heavy chain variable region is encoded by the nucleic acid sequence set forth as SEQ ID NO: 21 and the wherein the light chain variable regions is encoded by the nucleic acid sequence set forth SEQ ID NO: 22. 14. An isolated nucleic acid molecule encoding a heavy chain variable region comprising the amino acid sequence set forth as amino acids 26-33 of SEQ ID NO: 7, amino acids 51-58 of SEQ ID NO: 7, and amino acids 97-109 of SEQ ID NO: 7, wherein residue 56 is G and residue 109 is N; and wherein the heavy chain variable region, in conjunction with a light chain variable region, forms a human monoclonal antibody or antigen binding fragment that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 200 pM or less and specifically binds IGF-I with an equilibrium dissociation constant (Kd) of 200 pM or less. 15. The isolated nucleic acid molecule of claim 14, wherein the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 7, wherein residue 7 is L; residue 20 is V; residue 23 is K; residue 37 is V; residue 56 is G; residue 61 is A; residue 62 is Q; residue 74 is K; residue 76 is T; residue 77 is S; residue 79 is A; residue 85 is S; residue 87 is G; residue 109 is N; residue 111 is G; and residue 115 is L. 16. The isolated nucleic acid molecule of claim 14, wherein the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 7. 17. The isolated nucleic acid molecule of claim 14, comprising the nucleic acid sequence set forth as SEQ ID NO: 11, SEQ ID NO: 19, or SEQ ID NO: 21. 18. The isolated nucleic acid molecule of claim 14, operably linked to a promoter. 19. A vector comprising the isolated nucleic acid molecule of claim 18. 20. An isolated host cell transformed with the vector of claim 19. 21. A composition comprising the isolated nucleic acid molecule of claim 18 and a pharmaceutically acceptable carrier. 22. An isolated nucleic acid molecule encoding a light chain variable region comprising the amino acid sequence set forth as amino acids 27-32 of SEQ ID NO: 8, amino acids 50-52 of SEQ ID NO: 8 and amino acids 89-97 of SEQ ID NO: 8, wherein the light chain variable region, in conjunction with a heavy chain variable forms a human monoclonal antibody or antigen binding fragment that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 200 pM or less and specifically binds IGF-I with an equilibrium dissociation constant (Kd) of 200 pM or less. 23. The isolated nucleic acid molecule of claim 22, wherein the light chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 8. 24. The isolated nucleic acid molecule of claim 22, comprising the nucleic acid sequence set forth as SEQ ID NO: 12 or SEQ ID NO: 22. 25. The isolated nucleic acid molecule of claim 22, operably linked to a promoter. 26. A composition comprising the isolated nucleic acid molecule of claim 25, and a pharmaceutically acceptable carrier. 27. A vector comprising the isolated nucleic acid molecule of claim 25. 28. An isolated host cell transformed with the vector of claim 27.
Harpold Michael M. (El Cajon CA) Brust Paul (San Diego CA), Assay methods and compositions for detecting and evaluating the intracellular transduction of an extracellular signal.
Harpold Michael M. (San Diego CA) Brust Paul (San Diego CA), Assay methods and compositions useful for measuring the transduction of an intracellular signal.
Kay Robert M. (San Francisco CA) Berns Anton (Spaarndam NLX) Krimpenfort Paul (Heemstede NLX) Pieper Frank (Utrecht NLX) Strijker Rein (Oegstgeest NLX), Homologous recombination in mammalian cells.
Dunn Barbara (Los Altos CA) Choi Theodore K. (Berkeley CA), Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating.
Johnson Kevin Stuart,GBX ; Winter Gregory Paul,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX ; Waterhouse Peter Michael,AUX, Methods for producing members of specific binding pairs.
Buttram Scott (Downingtown PA) Dean Richard T. (Downingtown PA) Lister-James John (Glenmoore PA) Pak Koon Yan (Norristown PA), One vial method for labeling antibodies with Technetium-99m.
Queen Cary L. (Los Altos CA) Schneider William P. (Mountain View CA) Selick Harold E. (Belmont CA), Polynucleotides encoding improved humanized immunoglobulins.
Clark Steven C. (Winchester MA) Ciarletta Agnes B. (Tewksbury MA) Yang Yu-Chung (Arlington MA), Primate hematopoietic growth factors IL-3 and pharmaceutical compositions.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Rostoker Michael D. (Boulder Creek CA) Stelliga D. Tony (Pleasanton CA) Paolino Dave (Andover MA) Engelse Willem A. H. (Townsend MA), Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (C.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Deboer Herman A.,NLX ; Strijker Rein,NLX ; Heyneker Herbert L. ; Platenburg Gerard,NLX ; Lee Sang He,NLX ; Pieper Frank,NLX ; Krimpenfort Paul J. A.,NLX, Transgenic bovine.
Jakobovits,Aya; Kucherlapati,Raju; Klapholz,Susan; Mendez,Michael J; Green,Larry, Transgenic mammals having human Ig loci including plural Vand Vregions and antibodies produced therefrom.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.